IV OR SQRHIL2 IN HIV INFECTED SUBJECTS ON HAART
IV OR SQRHIL2 IN HIV INFECTED SUBJECTS ON HAART
批准号:
6415301
负责人:
CAROL S DUKES-HAMILTON
金额:
$29.31万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-12-01 至 2001-11-30
中文摘要
本研究的主要假设是,与单独进行高活性抗逆转录病毒治疗相比,不同途径间歇给药的rhIL-2(静脉注射与皮下注射)与高活性抗逆转录病毒治疗之间,在rhIL-2治疗一年后CD4计数比随机化前基线值增加50%的受试者比例和CD4计数变化率方面存在差异。该研究还将测试这些方案的安全性、耐受性和对生活质量的影响之间是否存在差异,以及在rhIL-2环境下使用HAART与单独使用HAART相比,在免疫细胞表型和功能、HIV病毒载量和抗病毒药物耐药性发展方面是否存在可测量的变化。方法:这是一项随机研究,旨在确定在CD4细胞计数为50- 300细胞/mm3的HIV患者中,持续静脉滴注高剂量间歇给予rhIL-2与皮下注射联合高活性抗逆转录病毒治疗相比,单独给予高活性抗逆转录病毒治疗对CD4反应的影响。受试者必须未经蛋白酶抑制剂治疗。所有受试者将接受茚地那韦和2种核苷类似物的治疗;其中一个是该学科的新技术(HAART)。受试者将接受12周的HAART治疗。在第10周,Chiron将通过bDNA进行HIV RNA(实时)检测。< 5000拷贝/ml的受试者将继续研究。如果受试者的浓度为5000拷贝/ml,则不需要进一步随访,应停止研究。HIV RNA < 5000拷贝/ml的受试者将被随机分配继续HAART或HAART联合rhIL-2,每8周持续输注900万单位(CIV) 5天,持续72周或9个周期,或rhIL-2,每天皮下注射750万单位,每天两次,每8周持续5天,持续72周或9个周期。CIV rhIL-2组的受试者在3个周期或6个周期后,CD4计数比随机化前基线值增加25%且至少增加100个细胞/mm3,将在7.5 MIU时通过皮下注射,每天两次,每8周注射5天,在其余疗程中切换到rhIL-2。结果和未来计划:该研究仍在进行中,治疗组仍为盲法,因此研究结论和意义尚不能讨论。该研究正在继续招募患者,并将继续这样做,直到达到全国的招募目标。意义:对许多HIV感染患者来说,免疫功能的改善仍然是一个虚幻的目标。这项研究将有助于开发HIV感染患者的免疫修复疗法。
英文摘要
The primary hypothesis of this study is that there will be a difference between different routes of intermittently administered rhIL-2 (IV vs subcutaneous admininistration) with a highly active antiretroviral regimen compared to highly active antiretroviral therapy alone with respect to the proportion of subjects achieving 50% increase in CD4 counts above pre-randomization baseline values after one year of rhIL-2 and the rate of change in CD4 counts. The study will also test whether there is a difference between the safety, tolerance, and effect on quality of life of these regimensand whether there are measureable changes in immune cell phenotypes and function and on HIV viral load and rate of antiviral drug resistance development when HAART is used in the setting of rhIL-2 compared to HAART alone. Methods: This is a randomized study to ascertain the effect on CD4 response of high dose, intermittently administered rhIL-2 administered by continuous intravenous infusion versus subcutaneous injections in conjunction with highly active antiretroviral therapy versus highly active antiretroviral therapy alone in patients with HIV and CD4 counts of 50- 300 cells/mm3. Subjects must be protease inhibitor therapy naive. All subjects will receive treatment with indinavir and 2 nucleoside analogues; one of which is new to the subject (HAART). Subjects will receive 12 weeks of HAART. At week 10 an HIV RNA by bDNA (real time) will be done by Chiron. Subjects with < 5,000 copies/ml will be continued on study. Subjects with > 5,000 copies/ml will require no further follow-up and should be taken off study. Subjects who have <5,000 copies/ml of HIV RNA will then be randomized to continue HAART alone or HAART with rhIL-2 at either 9 million units by continuous infusion (CIV) for 5 days every 8 weeks for 72 weeks, or 9 cycles, or rhIL-2 at 7.5 million units by subcutaneous injection twice a day for 5 days every 8 weeks for 72 weeks or 9 cycles. Subjects on the CIV rhIL-2 arm who achieve both a 25% increase and at least a 100 cell/mm3 increase in CD4 count above the prerandomization baseline value after 3 cycles or after 6 cycles will switch to rhIL-2 at 7.5 MIU by subcutaneous injection twice a day for 5 days every 8 weeks for the remainder of their treatment course. Results and Future Plans: The study is ongoing and treatment arms remain blinded, therefore study conclusions and significance can not yet be discussed. The study is continuing to enroll patients and will continue to do so until national enrollment goals are met. Significance: Improvement in immune function remains an illusive goal for many patients with HIV infection. This study will aid in developing immune restorative therapies for patients with HIV infection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RIFAPENTINE FOR RELAPSE AMONG HIV SEROPOSITIVE & SELECTED SERONEGATIVE
-
批准号:6565305
-
项目类别:
-
资助金额:$11.7万
-
财政年份:2001
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
IV OR SQRHIL2 IN HIV INFECTED SUBJECTS ON HAART
-
批准号:6565360
-
项目类别:
-
资助金额:$11.7万
-
财政年份:2001
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
ANTIRETROVIRAL ACTIVITY OF HYDROXYUREA ALONE AND IN COMBINATION WITH DDI
-
批准号:6565357
-
项目类别:
-
资助金额:$11.7万
-
财政年份:2001
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
IV OR SQRHIL2 IN HIV INFECTED SUBJECTS ON HAART
-
批准号:6463063
-
项目类别:
-
资助金额:$11.7万
-
财政年份:2000
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
ANTIRETROVIRAL ACTIVITY OF HYDROXYUREA ALONE AND IN COMBINATION WITH DDI
-
批准号:6503097
-
项目类别:
-
资助金额:$11.7万
-
财政年份:2000
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
RIFAPENTINE FOR RELAPSE AMONG HIV SEROPOSITIVE & SELECTED SERONEGATIVE
-
批准号:6463008
-
项目类别:
-
资助金额:$11.7万
-
财政年份:2000
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
ANTIRETROVIRAL ACTIVITY OF HYDROXYUREA ALONE AND IN COMBINATION WITH DDI
-
批准号:6463060
-
项目类别:
-
资助金额:$11.7万
-
财政年份:2000
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
RIFAPENTINE FOR RELAPSE AMONG HIV SEROPOSITIVE & SELECTED SERONEGATIVE
-
批准号:6415246
-
项目类别:
-
资助金额:$29.31万
-
财政年份:2000
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
ANTIRETROVIRAL ACTIVITY OF HYDROXYUREA ALONE AND IN COMBINATION WITH DDI
-
批准号:6415298
-
项目类别:
-
资助金额:$29.31万
-
财政年份:2000
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
RIFAPENTINE FOR RELAPSE AMONG HIV SEROPOSITIVE & SELECTED SERONEGATIVE
-
批准号:6503045
-
项目类别:
-
资助金额:$11.7万
-
财政年份:2000
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
IV OR SQRHIL2 IN HIV INFECTED SUBJECTS ON HAART
-
批准号:6503100
-
项目类别:
-
资助金额:$11.7万
-
财政年份:2000
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
RIFAPENTINE FOR RELAPSE AMONG HIV SEROPOSITIVE & SELECTED SERONEGATIVE
-
批准号:6302909
-
项目类别:
-
资助金额:$4.09万
-
财政年份:1999
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
ANTIRETROVIRAL ACTIVITY OF HYDROXYUREA ALONE AND IN COMBINATION WITH DDI
-
批准号:6112780
-
项目类别:
-
资助金额:$4.09万
-
财政年份:1998
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
IV OR SQRHIL2 IN HIV INFECTED SUBJECTS ON HAART
-
批准号:6112784
-
项目类别:
-
资助金额:$4.09万
-
财政年份:1998
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
RIFAPENTINE FOR RELAPSE AMONG HIV SEROPOSITIVE & SELECTED SERONEGATIVE
-
批准号:6263407
-
项目类别:
-
资助金额:$4.09万
-
财政年份:1998
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
ANTIRETROVIRAL ACTIVITY OF HYDROXYUREA ALONE AND IN COMBINATION WITH DDI
-
批准号:6274014
-
项目类别:
-
资助金额:$2.88万
-
财政年份:1997
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
IV OR SQRHIL2 IN HIV INFECTED SUBJECTS ON HAART
-
批准号:6274018
-
项目类别:
-
资助金额:$2.88万
-
财政年份:1997
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
PHASE I STUDY OF TESTODERMR-TTS IN HYPOGONADAL MALES WITH/WITHOUT AIDS
-
批准号:6243971
-
项目类别:
-
资助金额:$3.24万
-
财政年份:1975
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
ANTIRETROVIRAL ACTIVITY OF HYDROXYUREA ALONE AND IN COMBINATION WITH DDI
-
批准号:6302961
-
项目类别:
-
资助金额:$4.09万
-
财政年份:--
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
海外基金